Knopp Biosciences LLC

Knopp Biosciences LLC is a privately held holding company based in Pittsburgh, Pennsylvania, founded in 2004.

Originally established as Knopp Neurosciences Inc., the company was renamed to honor Walter Knopp, a local entrepreneur and philanthropist. As of 2022, Knopp has transitioned from drug development to managing a portfolio of equity securities and contract rights from previous drug spin-off and sale transactions. The company holds approximately 38% ownership in Areteia Therapeutics, Inc., which focuses on treatments for eosinophilic asthma and hypereosinophilic syndrome. Knopp also retains equity and future royalty rights from its past drug development efforts, including the Kv7 platform, which targets epilepsy and related disorders. With a small team, Knopp has raised $202 million in funding from notable investors, including Starpath Ventures and Biogen. The company continues to benefit financially from its legacy in immunological and neurological medicine.